Results 191 to 200 of about 30,536 (239)

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States. [PDF]

Blood Neoplasia
Mukherjee S, Dong W, Gerds AT, Carraway HE, Singh A, Advani AS, Mustafa Ali MK, Molina JC, Balderman S, Jain A, Caimi P, Anwer F, Sekeres MA, Koroukian SM.   +13 more
europepmc   +1 more source

Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives. [PDF]

Biomedicines
Dedes N, Liontos M, Haidopoulos D, Zagouri F, Angelou K, Svarna A, Michas A, Aravantinou Fatorou A, Andrikopoulou A, Dimopoulos MA.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Decitabine

Nature Reviews Drug Discovery, 2006
Decitabine is a hypomethylating agent. Its action in DNA leads to the reactivation of tumour suppressor genes and the subsequent differentiation of cancer cells. In a randomised, phase III trial in patients (n = 170) with myelodysplastic syndromes (MDS), intravenous decitabine (45 mg/m(2)/day for 3 consecutive days every 6 weeks) combined with ...
Kate, McKeage, Katherine F, Croom
exaly   +4 more sources

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

Nature Communications, 2021
Insufficient eradication capacity and dysfunction are common occurrences in T cells that characterize cancer immunotherapy failure. De novo DNA methylation promotes T cell exhaustion, whereas methylation inhibition enhances T cell rejuvenation in vivo ...
Yao Wang, Deyun Chen
exaly   +2 more sources

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Lancet Haematology,the, 2020
Courtney D Dinardo, Abhishek Maiti Mbbs, Caitlin R Early   +2 more
exaly   +2 more sources

Decitabine

Reactions Weekly, 2009
The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.
Daskalakis, Michael, Blagitko-Dorfs, Nadja, Hackanson, Björn   +2 more
  +6 more sources

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Cancer, 2023
Patients with acute myeloid leukemia (AML) who have tumor protein p53 (TP53) mutations or a complex karyotype have a poor prognosis, and hypomethylating agents are often used.
V. Duong, A. Ruppert, A. Mims, U. Borate, E. Stein, M. Baer, W. Stock, T. Kovacsovics, W. Blum, M. Arellano, G. Schiller, R. Olin, J. Foran, M. Litzow, Tara L. Lin, P. Patel, M. Foster, R. Redner, Zeina A Al-Mansour, C. Cogle, R. Swords, R. Collins, J. Vergilio, N. Heerema, Leonard Rosenberg, Ashley O Yocum, S. Marcus, Timothy L Chen, Franchesca Druggan, Mona Stefanos, T. Gana, A. Shoben, B. Druker, A. Burd, J. Byrd, R. Levine, M. Boyiadzis   +36 more
semanticscholar   +1 more source

Cladribine‐ and decitabine‐containing conditioning regimen has a low post‐transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

International Journal of Cancer, 2023
To reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), there have been continuing efforts to optimize the conditioning regimens.
X. Tong, Mengyuan Li, J. Jin, Yi Li, Li Li, Yizhou Peng, Lifang Huang, Bin Xu, Fankai Meng, X. Mao, Liang Huang, Wei Huang, Donghua Zhang   +12 more
semanticscholar   +1 more source